Salmeterol

also known as salmeterol xinafoate · SAL · LIPO-202 · Serevent · SEREVENT DISKUS · SALM · 408DP-02 · Racemic formoterol · +6 more

Other / unclassified

Developed for: asthma · chronic obstructive pulmonary disease · exercise-induced bronchoconstriction · abdominal wall malformation · allergic asthma · chronic bronchitis · pulmonary emphysema · bronchiectasis
+9 more
· cystic fibrosis · diastasis recti and weakness of the linea alba · environmental induced asthma · high altitude pulmonary edema · lipodystrophy · lung disorder · transplant-related bronchiolitis obliterans · allergic rhinitis · spinal cord injury
Investigated by: GlaxoSmithKline · Boehringer Ingelheim · Neothetics, Inc · Novartis Pharmaceuticals · AstraZeneca · National Heart, Lung, and Blood Institute (NHLBI)
+66 more
· Novartis · Teva Branded Pharmaceutical Products R&D, Inc. · University of Copenhagen · Milton S. Hershey Medical Center · Evofem Inc. · Organon and Co · Orion Corporation, Orion Pharma · Parexel · Taipei Veterans General Hospital, Taiwan · University of British Columbia · University of Milan · Università degli Studi di Ferrara · Academisch Ziekenhuis Groningen · Actavis Inc. · Allergy and Asthma Center of El Paso · Assistance Publique - Hôpitaux de Paris · Assiut University · Asthma Clinical Research Network · Bispebjerg Hospital · Brian J Lipworth · Brighton and Sussex University Hospitals NHS Trust · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chiesi Farmaceutici S.p.A. · Childhood Asthma Research and Education Network · Cipla Ltd. · Elpen Pharmaceutical Co. Inc. · European Research Council · FLUIDDA nv · Far Eastern Memorial Hospital · Fondazione Salvatore Maugeri · Fraunhofer-Institute of Toxicology and Experimental Medicine · Hanmi Pharmaceutical Company Limited · Hormone Laboratory, Aker University Hospital, Oslo, Norway · Imperial College London · Inje University · JHSPH Center for Clinical Trials · Kindeva Drug Delivery · Leiden University Medical Center · McGill University Health Centre/Research Institute of the McGill University Health Centre · Merck Sharp & Dohme LLC · National Center for Research Resources (NCRR) · National Jewish Health · National Taiwan University Hospital · Nemours Children's Clinic · Netherlands Organisation for Scientific Research · Neutec Ar-Ge San ve Tic A.Ş · Northwestern University · Parc de Salut Mar · Pfizer · Professor Warren Lenney · Queen's University · Respirent Pharmaceuticals Co Ltd. · Seoul National University Hospital · Shanghai Pulmonary Hospital, Shanghai, China · Shin-hwar Wu · Sumitomo Pharma America, Inc. · The Netherlands Asthma Foundation · United States Department of Defense · University of California, Los Angeles · University of Colorado, Denver · University of Dundee · University of Miami · University of Rostock · University of Southampton · University of Sussex · University of Wisconsin, Madison

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Aerivio Spiromax	—	2016-08-18	europa.eu ↗
Refused (EMA)	EU (EMA)	Labazenit	—	2013-09-06	europa.eu ↗

Trials 153 · started per year

today

EU approved 2016

20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT05748977	Feb 2023 → Feb 2024	chronic obstructive pulmonary disease	Assiut University	Unknown	No outcome recorded
Phase 115 trials
Phase 1	NCT04195867	Nov 2018 → Jan 2019	—	Parc de Salut Mar	Completed	No outcome recorded
Phase 1	NCT03238482	Aug → Dec 2017	asthma	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT02441114	Jul → Oct 2015	chronic obstructive pulmonary disease	Seoul National University Hospital	Completed	No outcome recorded
Phase 1	NCT02437604	May → Jul 2015	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 1	NCT02218762	Oct 2014 → Jun 2015	asthma	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 1	NCT02232087	Jul → Oct 2014	—	Kindeva Drug Delivery	Completed	No outcome recorded
Phase 1	NCT01890863	Aug → Sep 2013	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01564199	Apr → Jun 2012	—	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT01521455	Feb 2012 → Jun 2013	asthma	Hanmi Pharmaceutical Company Limited	Completed	No outcome recorded
Phase 1	NCT01540708	Jan → Sep 2012	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT02254174	Mar → Jul 2006	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02254187	Sep → Oct 2005	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00364273	Aug 2005 → Jul 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00364442	Jan → Apr 2005	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT02254226	Nov 2004 → Jan 2005	—	Boehringer Ingelheim	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT06040268	Dec 2023 → Dec 2026 expected	high altitude pulmonary edema	University of Colorado, Denver	Recruiting	No outcome recorded
Phase 1/2	NCT01494610	Oct 2010 → Jun 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 218 trials
Phase 2	NCT03005717	Dec 2016 → Jun 2017	—	Neothetics, Inc	Completed	No outcome recorded
Phase 2	NCT02568319	Sep → Dec 2015	abdominal wall malformation	Neothetics, Inc	Completed	No outcome recorded
Phase 2	NCT02397525	Mar 2015 → Jun 2016	abdominal wall malformation	Neothetics, Inc	Unknown	No outcome recorded
Phase 2	NCT02833480	Feb 2015 → Jan 2021	chronic obstructive pulmonary disease	University of British Columbia	Unknown	No outcome recorded
Phase 2	NCT01802723	Feb → Jun 2013	lipodystrophy	Neothetics, Inc	Completed	No outcome recorded
Phase 2	NCT01048333	Jan → May 2010	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00557440	Nov 2007 → Apr 2008	asthma	Novartis	Completed	No outcome recorded
Phase 2	NCT00556673	Oct 2007 → Apr 2008	asthma	Novartis	Completed	No outcome recorded
Phase 2	NCT00531050	Aug 2007 → Jun 2008	chronic obstructive pulmonary disease	Novartis	Completed	No outcome recorded
Phase 2	NCT00468975	May 2007 → ?	asthma	Pfizer	Completed	No outcome recorded
Phase 2	NCT00403754	Nov 2006 → Nov 2007	asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00422604	Oct 2006 → May 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00350207	Jul 2006 → Sep 2008	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00358488	Apr 2006 → Jan 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00325169	Dec 2005 → Aug 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT02238106	Sep 2005 → Feb 2006	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02242227	Sep 2005 → Feb 2006	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02242253	Sep 2003 → Jul 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded

Phase 342 trials
Phase 3	NCT05776927	May 2026 → Dec 2028 expected	asthma	Novartis Pharmaceuticals	Not yet recruiting	No outcome recorded
Phase 3	NCT04655508	May 2021 → Sep 2023	disease related to hematopoietic stem cell transplant, transplant-related bronchiolitis obliterans	Assistance Publique - Hôpitaux de Paris	Terminated	No outcome recorded
Phase 3	NCT03394989	Oct 2018 → Dec 2019	asthma	Cipla Ltd.	Completed	No outcome recorded
Phase 3	NCT03676413	Oct 2018 → Aug 2019	asthma	Respirent Pharmaceuticals Co Ltd.	Completed	No outcome recorded
Phase 3	NCT03461627	Apr 2017 → Oct 2018	asthma	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT02980133	Dec 2016 → Apr 2019	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT02496715	Sep 2015 → Oct 2016	asthma	Actavis Inc.	Withdrawn	No outcome recorded
Phase 3	NCT02483533	Jun → Dec 2015	diastasis recti and weakness of the linea alba	Evofem Inc.	Terminated	No outcome recorded
Phase 3	NCT02398188	Apr → Oct 2015	abdominal wall malformation	Evofem Inc.	Completed	No outcome recorded
Phase 3	NCT02397499	Apr → Dec 2015	—	Neothetics, Inc	Completed	No outcome recorded
Phase 3	NCT02301975	Mar 2015 → Nov 2016	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02175771	Jul 2014 → Jul 2015	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT01967173	Feb 2014 → Jul 2017	asthma	Milton S. Hershey Medical Center	Completed	No outcome recorded
Phase 3	NCT01978145	Nov 2013 → Apr 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01978119	Nov 2013 → Jan 2015	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01795664	Mar → Aug 2013	asthma	FLUIDDA nv	Completed	No outcome recorded
Phase 3	NCT01079130	Feb → Jul 2010	asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00673478	May 2008 → Jun 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00668772	Apr → Nov 2008	chronic obstructive pulmonary disease	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 3	NCT00662792	Apr 2008 → Jul 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01484210	Mar → Aug 2008	asthma	Elpen Pharmaceutical Co. Inc.	Completed	No outcome recorded
Phase 3	NCT00615030	Jan → Jul 2008	chronic obstructive pulmonary disease	Novartis	Completed	No outcome recorded
Phase 3	NCT00622635	Jan → Jul 2008	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00529529	Sep 2007 → Aug 2008	asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00449046	Mar → Nov 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00395304	Mar 2007 → Dec 2011	asthma	Milton S. Hershey Medical Center	Completed	No outcome recorded
Phase 3	NCT00441441	Feb 2007 → Jan 2008	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00411372	Nov 2006 → ?	chronic obstructive pulmonary disease	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 3	NCT00127166	Dec 2005 → Nov 2008	exercise-induced bronchoconstriction	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00245570	Dec 2005 → Sep 2006	exercise-induced bronchoconstriction	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00328718	Oct 2005 → Apr 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00242775	May 2005 → May 2006	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00269126	Feb → Aug 2005	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00252863	Dec 2004 → May 2006	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00200967	Dec 2004 → Feb 2008	asthma	Milton S. Hershey Medical Center	Completed	No outcome recorded
Phase 3	NCT00549146	Nov 2003 → Apr 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00268177	Oct 2002 → Dec 2003	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00272506	Aug 2002 → Sep 2004	asthma, lung disorder	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 3	NCT00274560	May 2002 → Mar 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00920959	Nov 2001 → Jan 2004	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00274534	Dec 2000 → Jul 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00268216	Sep 2000 → Nov 2005	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded

Phase 461 trials
Phase 4	NCT04503460	Jul 2021 → Sep 2024	asthma	Imperial College London	Unknown	No outcome recorded
Phase 4	NCT04677959	Feb 2021 → Mar 2022	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 4	NCT03662711	Nov 2018 → Oct 2022	chronic obstructive pulmonary disease	Università degli Studi di Ferrara	Terminated	No outcome recorded
Phase 4	NCT03363503	Apr 2018 → Apr 2022	chronic obstructive pulmonary disease	Neutec Ar-Ge San ve Tic A.Ş	Terminated	No outcome recorded
Phase 4	NCT03269318	Jul 2017 → Aug 2019	asthma	Brighton and Sussex University Hospitals NHS Trust	Terminated	No outcome recorded
Phase 4	NCT03034915	Jun 2017 → Jun 2018	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT02558088	Sep 2014 → Jul 2016	—	University of Copenhagen	Completed	No outcome recorded
Phase 4	NCT02546349	Jul 2014 → Dec 2015	chronic obstructive pulmonary disease	Taipei Veterans General Hospital, Taiwan	Unknown	No outcome recorded
Phase 4	NCT01853787	Jul 2014 → Jun 2015	chronic obstructive pulmonary disease	University of Milan	Completed	No outcome recorded
Phase 4	NCT02055352	May 2014 → Jan 2016	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02113436	May 2014 → Jun 2016	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT02061280	Oct 2013 → Feb 2017	asthma	Nemours Children's Clinic	Completed	No outcome recorded
Phase 4	NCT01794780	Feb 2013 → May 2015	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01762800	Feb 2013 → Sep 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01536587	Jul → Nov 2012	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01607398	May 2012 → Jul 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01475721	Nov 2011 → Jun 2015	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01462344	Nov 2011 → Nov 2015	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01361984	Jun 2011 → Jun 2013	chronic bronchitis, pulmonary emphysema	University of California, Los Angeles	Unknown	No outcome recorded
Phase 4	NCT02782312	Jun 2011 → Jun 2012	bronchiectasis	Shanghai Pulmonary Hospital, Shanghai, China	Completed	No outcome recorded
Phase 4	NCT01192178	Aug → Dec 2010	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01124422	Jul 2010 → May 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00974805	Feb 2010 → Feb 2012	chronic obstructive pulmonary disease	University of Southampton	Completed	No outcome recorded
Phase 4	NCT01131806	Dec 2009 → Nov 2010	chronic obstructive pulmonary disease	Taipei Veterans General Hospital, Taiwan	Unknown	No outcome recorded
Phase 4	NCT01194700	Nov → Dec 2009	asthma	Brian J Lipworth	Completed	No outcome recorded
Phase 4	NCT00984659	Oct 2009 → Jul 2010	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00914901	Jul 2009 → Mar 2011	asthma	Bispebjerg Hospital	Unknown	No outcome recorded
Phase 4	NCT00901368	May 2009 → Sep 2010	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 4	NCT01526161	Apr 2009 → Jun 2010	asthma	Professor Warren Lenney	Completed	No outcome recorded
Phase 4	NCT00830505	Apr 2009 → May 2010	asthma	University of Dundee	Completed	No outcome recorded
Phase 4	NCT00784550	Dec 2008 → Dec 2009	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00867737	Sep 2008 → Sep 2009	asthma	Allergy and Asthma Center of El Paso	Unknown	No outcome recorded
Phase 4	NCT02136875	Jul 2008 → Aug 2010	chronic obstructive pulmonary disease	McGill University Health Centre/Research Institute of the McGill University Health Centre	Completed	No outcome recorded
Phase 4	NCT00633217	Mar 2008 → Feb 2009	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00530842	Sep 2007 → Jan 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00517634	Aug 2007 → Jul 2008	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00712335	Feb 2007 → May 2011	environmental induced asthma	Inje University	Completed	No outcome recorded
Phase 4	NCT00346749	Dec 2006 → Jul 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Terminated	No outcome recorded
Phase 4	NCT00400608	Oct 2006 → Feb 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00379028	Sep 2006 → Jul 2007	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00363480	May 2006 → Sep 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00358358	Mar 2006 → Feb 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00353873	Nov 2005 → Oct 2006	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00291382	Nov 2005 → Jul 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00120978	Dec 2004 → Aug 2006	chronic obstructive pulmonary disease	University of British Columbia	Unknown	No outcome recorded
Phase 4	NCT00115492	Dec 2004 → Jun 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00315744	Nov 2004 → Apr 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00102765	Nov 2004 → Apr 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00102882	Oct 2004 → Jan 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00144911	Oct 2004 → Dec 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00355342	Apr 2004 → Sep 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00327353	Jan 2004 → ?	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00118716	Dec 2003 → Apr 2006	exercise-induced bronchoconstriction	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00118690	Dec 2003 → Dec 2005	exercise-induced bronchoconstriction	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00239421	Nov 2003 → Sep 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00950794	Sep 2003 → Feb 2005	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00239499	Sep 2003 → Aug 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00361959	Jun 2003 → Feb 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00156819	Jun 2003 → Aug 2005	asthma	JHSPH Center for Clinical Trials	Completed	No outcome recorded
Phase 4	NCT00479739	Nov 2002 → Jul 2004	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00158847	Apr 2000 → May 2005	chronic obstructive pulmonary disease	Leiden University Medical Center	Terminated	No outcome recorded

Phase not applicable14 trials
—	NCT06655012	Oct 2024 → Dec 2026 expected	—	University of Copenhagen	Recruiting	No outcome recorded
—	NCT06654986	Oct 2024 → Dec 2026 expected	—	University of Copenhagen	Recruiting	No outcome recorded
—	NCT06657547	Oct 2024 → Dec 2026 expected	—	University of Copenhagen	Recruiting	No outcome recorded
—	NCT03524066	Apr → Dec 2018	—	Fraunhofer-Institute of Toxicology and Experimental Medicine	Completed	No outcome recorded
—	NCT02758873	Feb 2016 → Jul 2019	asthma	University of Sussex	Completed	No outcome recorded
—	NCT01933984	Aug 2013 → Jan 2019	chronic obstructive pulmonary disease	Shin-hwar Wu	Completed	No outcome recorded
—	NCT01271556	Dec 2008 → Mar 2009	chronic obstructive pulmonary disease	University of Milan	Completed	No outcome recorded
—	NCT00741767	Aug 2008 → Sep 2010	chronic obstructive pulmonary disease, sleep disorder	Northwestern University	Withdrawn	No outcome recorded
—	NCT00559312	Dec 2007 → Mar 2010	chronic obstructive pulmonary disease	Queen's University	Completed	No outcome recorded
—	NCT01231230	May 2007 → Dec 2009	asthma	University of Miami	Completed	No outcome recorded
—	NCT00736801	Sep 2005 → Jan 2007	allergic asthma	University of Rostock	Completed	No outcome recorded
—	NCT00214019	Nov 2003 → Jan 2008	allergic asthma	University of Wisconsin, Madison	Completed	No outcome recorded
—	NCT00233051	Apr 2003 → Jun 2006	chronic bronchitis, pulmonary emphysema	National Jewish Health	Terminated	No outcome recorded
—	NCT00005110	—	cystic fibrosis	National Center for Research Resources (NCRR)	Suspended	No outcome recorded

Also used as a comparator or background therapy in 132 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 16 trials
Phase 1	NCT02474017 Background	May → Jun 2015	asthma, chronic obstructive pulmonary disease	Mylan Pharma UK Ltd.	Completed	No outcome recorded
Phase 1	NCT02162485 Comparator	Jun 2014 → Sep 2015	asthma	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT01355991 Comparator	Aug 2011 → Mar 2016	spinal cord injury	James J. Peters Veterans Affairs Medical Center	Unknown	No outcome recorded
Phase 1	NCT00908362 Comparator	May → Oct 2009	chronic obstructive pulmonary disease	University of Rostock	Completed	No outcome recorded
Phase 1	NCT02256722 Comparator	Oct → Nov 2005	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00116402 Comparator	Jan 2005 → Sep 2009	chronic obstructive pulmonary disease	University of Chicago	Completed	No outcome recorded

Phase 219 trials
Phase 2	NCT06676319 Background	Nov 2024 → Jun 2027 expected	asthma	Sanofi	Active not recruiting	No outcome recorded
Phase 2	NCT03207243 Background	Sep 2017 → Feb 2019	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT03063086 Comparator	Jan 2017 → Aug 2018	asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT02573233 Background	Jan 2016 → Jan 2018	asthma	Sanofi	Completed	No outcome recorded
Phase 2	NCT01636076 Comparator	Nov 2012 → Sep 2013	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01312961 Background	Mar 2011 → Oct 2012	asthma	Sanofi	Completed	No outcome recorded
Phase 2	NCT01319019 Comparator	Dec 2010 → Sep 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01248975 Background	Dec 2010 → Oct 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01209715 Comparator	Oct 2010 → May 2012	chronic obstructive pulmonary disease	University of Miami	Withdrawn	No outcome recorded
Phase 2	NCT01156792 Comparator	Sep 2010 → Oct 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00808288 Comparator	Mar → Dec 2010	chronic obstructive pulmonary disease	Pfizer	Completed	No outcome recorded
Phase 2	NCT01070524 Comparator	Jan → Jul 2010	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT00927758 Comparator	Jun → Dec 2009	asthma	Sandoz	Completed	No outcome recorded
Phase 2	NCT00640484 Comparator	Apr → Oct 2008	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT00535366 Background	Oct 2007 → Sep 2008	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00605891 Comparator	Oct 2006 → Jun 2007	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT00347139 Comparator	May 2006 → Jan 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00685529 Comparator	Apr → Oct 2005	chronic obstructive pulmonary disease	Sumitomo Pharma America, Inc.	Completed	No outcome recorded
Phase 2	NCT00354874 Comparator	Jan → Jun 2005	asthma	GlaxoSmithKline	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT02195375 Comparator	Sep 2014 → May 2016	chronic obstructive pulmonary disease	Mundipharma Research Limited	Completed	No outcome recorded
Phase 354 trials
Phase 3	NCT04208581 Background	Oct 2019 → Dec 2021	chronic obstructive pulmonary disease, respiratory failure	Peking University People's Hospital	Unknown	No outcome recorded
Phase 3	NCT03376932 Comparator	Jan 2019 → Feb 2021	asthma	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 3	NCT03756883 Comparator	Dec 2018 → Oct 2019	asthma	Actavis Inc.	Completed	No outcome recorded
Phase 3	NCT03562923 Comparator	Oct 2018 → May 2019	asthma	Amneal Ireland Limited	Unknown	No outcome recorded
Phase 3	NCT03158311 Comparator	Feb 2018 → Jul 2019	asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT03387241 Comparator	Jun 2017 → Dec 2019	asthma	Mundipharma (China) Pharmaceutical Co. Ltd	Unknown	No outcome recorded
Phase 3	NCT02924688 Background	Oct 2016 → Feb 2019	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02446418 Comparator	Jul 2015 → Jul 2017	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02477397 Comparator	May 2015 → Jun 2019	chronic obstructive pulmonary disease	University Medical Center Groningen	Unknown	No outcome recorded
Phase 3	NCT02270424 Background	Oct 2014 → Dec 2016	chronic obstructive pulmonary disease	Henan University of Traditional Chinese Medicine	Unknown	No outcome recorded
Phase 3	NCT02165826 Background	May 2014 → Sep 2015	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT01860066 Comparator	Dec 2013 → Sep 2014	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 3	NCT01834885 Comparator	Dec 2013 → Sep 2014	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 3	NCT01969721 Comparator	Oct 2013 → Jan 2015	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01908140 Comparator	Sep 2013 → Aug 2014	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT01782326 Comparator	Jul 2013 → Sep 2015	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01879410 Comparator	Jun 2013 → Jan 2014	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01822899 Comparator	Apr → Oct 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01817764 Comparator	Mar → Oct 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01772134 Background	Jan → Jul 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01772147 Comparator	Jan → Aug 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01709903 Comparator	Nov 2012 → Feb 2014	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01706328 Comparator	Oct 2012 → Jun 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01570478 Comparator	Jul 2012 → Feb 2014	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT01513460 Background	Apr 2012 → Dec 2013	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01511367 Comparator	Mar 2012 → Sep 2013	asthma	Mundipharma Research Limited	Completed	No outcome recorded
Phase 3	NCT01393145 Comparator	Aug 2011 → Aug 2012	chronic obstructive pulmonary disease	Ache Laboratorios Farmaceuticos S.A.	Withdrawn	No outcome recorded
Phase 3	NCT01245569 Comparator	Apr 2011 → Mar 2012	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT01290874 Comparator	Mar 2011 → Jul 2013	asthma	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 3	NCT01323634 Comparator	Mar → Dec 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01323621 Comparator	Mar 2011 → Jan 2012	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01315249 Comparator	Mar 2011 → Mar 2012	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01342913 Comparator	Feb → Oct 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01181895 Comparator	Sep 2010 → Aug 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01172821 Comparator	Aug 2010 → Nov 2012	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01172808 Comparator	Aug 2010 → Nov 2012	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01147848 Comparator	Jun 2010 → Jul 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01089127 Comparator	Mar → Jul 2010	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00876694 Comparator	Mar 2009 → Oct 2010	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00821093 Comparator	Jan → Oct 2009	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00662740 Comparator	Apr → Nov 2008	chronic obstructive pulmonary disease	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 3	NCT00567996 Comparator	Nov 2007 → Jan 2009	chronic obstructive pulmonary disease	Novartis	Completed	No outcome recorded
Phase 3	NCT00497237 Comparator	Apr 2007 → Mar 2010	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT00448435 Comparator	Apr 2007 → Jan 2008	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00424008 Comparator	Apr 2007 → Nov 2008	asthma	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00379288 Comparator	Jun 2006 → Nov 2007	asthma	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00314574 Background	Dec 2005 → Nov 2009	asthma	Genentech, Inc.	Completed	No outcome recorded
Phase 3	NCT00646594 Comparator	Nov 2003 → Jan 2005	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00064415 Comparator	Jun 2002 → Dec 2004	chronic bronchitis, pulmonary emphysema	Sumitomo Pharma America, Inc.	Completed	No outcome recorded
Phase 3	NCT02172794 Comparator	May 2002 → Oct 2005	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00064402 Comparator	Apr 2002 → Mar 2004	chronic bronchitis, pulmonary emphysema	Sumitomo Pharma America, Inc.	Completed	No outcome recorded
Phase 3	NCT00685841 Comparator	Feb 2002 → Jun 2003	chronic obstructive pulmonary disease	Sumitomo Pharma America, Inc.	Completed	No outcome recorded
Phase 3	NCT02173691 Comparator	Feb 1999 → May 2000	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172287 Comparator	Feb 1999 → May 2000	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded

Phase 439 trials
Phase 4	NCT06572228 Background	Aug 2024 → Apr 2027 expected	asthma	Regeneron Pharmaceuticals	Active not recruiting	No outcome recorded
Phase 4	NCT03395002 Comparator	Mar 2018 → Apr 2020	chronic obstructive pulmonary disease	Neutec Ar-Ge San ve Tic A.Ş	Completed	No outcome recorded
Phase 4	NCT03240575 Comparator	Aug 2017 → Apr 2019	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT03055988 Comparator	Mar 2017 → Mar 2018	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02972476 Comparator	Dec 2016 → Jul 2019	chronic obstructive pulmonary disease	University of Dundee	Completed	No outcome recorded
Phase 4	NCT02516592 Comparator	Oct 2015 → May 2017	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT03110874 Background	Oct 2015 → Sep 2016	asthma	Hanmi Pharmaceutical Company Limited	Completed	No outcome recorded
Phase 4	NCT02257372 Background	Sep 2014 → Mar 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT02388373 Comparator	Jul 2014 → Feb 2016	asthma	Research in Real-Life Ltd	Completed	No outcome recorded
Phase 4	NCT01907334 Comparator	Aug 2013 → May 2014	asthma	University of Florida	Completed	No outcome recorded
Phase 4	NCT01892787 Comparator	Jul 2013 → Dec 2014	asthma	University of Dundee	Completed	No outcome recorded
Phase 4	NCT01751113 Comparator	Feb → Nov 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01696214 Comparator	Oct 2012 → May 2015	asthma	University of California, San Diego	Completed	No outcome recorded
Phase 4	NCT01437995 Comparator	Mar 2012 → Sep 2015	asthma	Johns Hopkins University	Completed	No outcome recorded
Phase 4	NCT01555138 Comparator	Feb 2012 → Feb 2014	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01344655 Comparator	Apr 2011 → Sep 2012	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 4	NCT01110200 Comparator	Apr 2010 → Apr 2012	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01657487 Background	Apr 2010 → Sep 2012	—	Far Eastern Memorial Hospital	Unknown	No outcome recorded
Phase 4	NCT01243788 Comparator	Jul 2009 → Feb 2011	chronic obstructive pulmonary disease	Fudan University	Unknown	No outcome recorded
Phase 4	NCT00857766 Comparator	Mar 2009 → Mar 2010	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00975195 Background	Feb 2009 → Jul 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00731770 Comparator	Jan 2009 → Apr 2010	chronic obstructive pulmonary disease	Milton S. Hershey Medical Center	Completed	No outcome recorded
Phase 4	NCT00563381 Comparator	Jan 2008 → Apr 2010	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00456313 Comparator	Dec 2007	asthma	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 4	NCT00527826 Comparator	Nov 2007 → Jul 2009	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00503009 Comparator	Oct 2007 → Jul 2008	asthma	GlaxoSmithKline	Terminated	No outcome recorded
Phase 4	NCT01225913 Background	Oct 2007 → Jun 2027 expected	asthma	Gelb, Arthur F., M.D.	Recruiting	No outcome recorded
Phase 4	NCT01186653 Comparator	Oct 2007 → May 2010	chronic obstructive pulmonary disease	Hull University Teaching Hospitals NHS Trust	Completed	No outcome recorded
Phase 4	NCT01255579 Comparator	Jul 2007 → Dec 2008	asthma	University of Brescia	Completed	No outcome recorded
Phase 4	NCT00452699 Comparator	May 2007 → May 2009	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00452348 Comparator	May 2007 → Apr 2009	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01388595 Comparator	Nov 2006 → Oct 2010	allergic rhinitis	University of Dundee	Completed	No outcome recorded
Phase 4	NCT00525564 Comparator	May → Oct 2006	chronic obstructive pulmonary disease	Laval University	Completed	No outcome recorded
Phase 4	NCT00471809 Background	Mar 2006 → Mar 2007	asthma	National Heart, Lung, and Blood Institute (NHLBI)	Terminated	No outcome recorded
Phase 4	NCT00296491 Comparator	Sep 2005 → Oct 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00235053 Background	Aug → Nov 2005	asthma, oral candidiasis, voice disorders	Allergy & Asthma Medical Group & Research Center	Completed	No outcome recorded
Phase 4	NCT00351143 Background	Jul 2005 → Jun 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00197106 Comparator	Jun 2005 → Oct 2008	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00920543 Comparator	Feb 2003 → Oct 2004	asthma	GlaxoSmithKline	Completed	No outcome recorded

Phase not applicable13 trials
—	NCT07058259 Background	Nov 2024 → Jun 2025 overdue	chronic obstructive pulmonary disease	Istanbul Medeniyet University	Active not recruiting	No outcome recorded
—	NCT02790047 Background	Oct 2016 → Jan 2018	chronic obstructive pulmonary disease	Khon Kaen University	Unknown	No outcome recorded
—	NCT02415179 Comparator	May 2015 → Feb 2016	asthma	Mahidol University	Completed	No outcome recorded
—	NCT02556073 Background	Aug 2014 → Aug 2016	asthma	Taipei Veterans General Hospital, Taiwan	Unknown	No outcome recorded
—	NCT02024204 Comparator	Apr 2014 → May 2017	lung disorder	NYU Langone Health	Completed	No outcome recorded
—	NCT01391559 Comparator	Jul 2011 → Oct 2012	chronic obstructive pulmonary disease	Dartmouth-Hitchcock Medical Center	Completed	No outcome recorded
—	NCT01117116 Comparator	Mar 2010 → Sep 2013	asthma	National Jewish Health	Completed	No outcome recorded
—	NCT01213693 Comparator	May 2009 → May 2013	chronic obstructive pulmonary disease	Università degli Studi di Ferrara	Completed	No outcome recorded
—	NCT00706446 Comparator	Jun 2008 → Jun 2010	asthma	Brigham and Women's Hospital	Terminated	No outcome recorded
—	NCT00595361 Comparator	Jan 2008 → May 2011	asthma	Brigham and Women's Hospital	Completed	No outcome recorded
—	NCT00655616 Comparator	Aug 2007 → Aug 2009	asthma	University of Dundee	Completed	No outcome recorded
—	NCT00521222 Comparator	Jun 2007 → Nov 2010	asthma	Columbia University	Completed	No outcome recorded
—	NCT02318043 Comparator	Jan → Dec 2007	asthma	Guangzhou Institute of Respiratory Disease	Completed	No outcome recorded

Press releases naming this drug 5 releases

Date	Issuer	Release
2020-09-21	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder tevapharm.com ↗
2019-07-15	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder tevapharm.com ↗
2017-04-20	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol tevapharm.com ↗
2016-06-28	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FDA Acceptance of New Drug Applications for Fluticasone Propionate/Salmeterol and Fluticasone Propionate RespiClick® Inhalers tevapharm.com ↗
2015-11-19	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma tevapharm.com ↗

Evidence & citations 18 cited values

Every value below carries the sentence it was read from. 291 sources stand behind the page.

Field	Value	Cited text
Known as	Salmeterol	“A Multicenter, Randomized, Double-blind, Parallel Group, 40-week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long-term Treatment...” NCT00920543 ↗ 279 “This pilot study was designed to evaluate the pharmacokinetic characteristics of fluticasone, salmeterol, and tiotropium after co-administration of HCP 0910 (Seretide 250...” NCT02441114 ↗ “PURPOSE: Using sputum neutrophils as the primary measure, and other inflammation biomarkers, this study evaluated the anti-inflammatory effects of the combination salmeterol 50...” PMID 25945045 ↗ Apr 2015 “BACKGROUND: This study tested the clinical non-inferiority of the fluticasone propionate/salmeterol combination 50/250 μg (FSC) Rotacaps®/Rotahaler® system, a single unit dose...” PMID 28115223 ↗ Jan 2017 “Dual Therapy (LABA + LAMA): Patients receive a long-acting beta-agonist (LABA) such as Formoterol, Salmeterol, Olodaterol, Vilanterol, or Indacaterol, in combination with a...” NCT07058259 ↗ “Umeclidinium (UMEC; long-acting muscarinic antagonist [LAMA])/vilanterol (VI; long-acting beta2-agonist [LABA]) and fluticasone propionate/salmeterol (FP/SAL) (inhaled...” PMID 26006754 ↗ May 2015 “The purpose of this study is to optimise the device and/or formulation of the Fluticasone propionate (FP)/salmeterol (SALM) unit dose powder inhaler (Rotahaler) to achieve drug...” NCT01540708 ↗ “Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of...” NCT01110200 ↗ “compare Systemic Exposure and Pharmacodynamics of Fluticasone Propionate and Salmeterol Following Advair HFA 45/21mcg (2 Inhalations), ADVAIR® HFA 45/21mcg (2 Inhalations) With...” NCT00400608 ↗ “The combination of salmeterol and fluticasone propionate (SFC) and tiotropium bromide (TIO) are commonly used treatments in chronic obstructive pulmonary disease (COPD) but...” PMID 18245142 ↗ Feb 2008 “Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol...” NCT03376932 ↗ “ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a 100 mcg fluticasone propionate and a 50 mcg salmeterol. One inhalation from the DISKUS device twice daily (BID)...” NCT01192178 ↗ “OBJECTIVE: Characterize fluticasone propionate (Fp) and combination fluticasone propionate and salmeterol (FS) pharmacokinetic and safety profiles, delivered via a novel,...” PMID 28933971 ↗ Oct 2017 “For children between 6 to 11 years (\< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6...” NCT04655508 ↗ “Each patient will routinely receive 4 puffs of 25 mcg salmeterol /250 mcg fluticasone (Seretide Evohaler 250; GlaxoSmithKline Inc. Evreux, France) every 12 hours until the...” NCT01933984 ↗ “Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics:...” NCT02165826 ↗ “Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler in...” PMID 27599598 ↗ Sep 2016 “The study evaluated the efficacy of beclomethasone dipropionate/formoterol fumarate (BDP/FF) extrafine combination versus fluticasone propionate/salmeterol (FP/S) combination...” PMID 24621109 ↗ Mar 2014 “The participants were then randomized to budesonide/formoterol (Bud + Form; 400/12 μg BID), fluticasone/salmeterol (Flu + Salm; 250/50 μg BID), or formoterol only (12 μg BID)...” PMID 34464242 ↗ Nov 2021 “FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient.” NCT02175771 ↗ “Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)” NCT01570478 ↗ “A total of 300 children were assigned to one of three active treatment arms for 12 months: active ICS; a combination of active ICS and salmeterol; or active montelukast (LTRA).” NCT00272506 ↗ “Fluticasone Propionate / Formoterol Fumarate (Flutiform®) 500/20 µg BID and 250/10 µg BID Versus Salmeterol / Fluticasone (Seretide®) 50/500 µg BID” NCT02195375 ↗ “Single doses of placebo/Seretide 250 (total dose ex valve fluticasone 2000 mcg/salmeterol 200 mcg) were administered via the devices.” PMID 21240480 ↗ Jan 2011 “Fluticasone, an inhaled corticosteroid and salmeterol, a long-acting beta agonist, are approved for use in the management of COPD.” NCT00731770 ↗ “These patients will never have been prescribed the components present in Seretide (Salmeterol and Flixotide or similar compounds).” NCT00974805 ↗ “Fluticasone propionate and Salmeterol delivered in a capsule-based inhaler versus a multi-dose dry powder inhaler” NCT01494610 ↗ “Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation” NCT02113436 ↗ “Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : one-way education” NCT03110874 ↗ “Salmeterol / Fluticasone Powder for Inhalation will be used twice daily (50ug/250ug each time) for 52 weeks” NCT04208581 ↗ “Fluticasone 250 µg + salmeterol 50 µg DPI (Seretide® Diskus®) 1 inhalation b.i.d. (daily dose 500+100 µg)” NCT00901368 ↗ “Inhaled Fenotereol,Ipratroium Plus Beclomethasone Versus Salmeterol,Tiotropium Plus Fluticasone” NCT05748977 ↗ “the LABA salmeterol (50 μg) plus the inhaled glucocorticoid fluticasone (500 μg) twice daily” PMID 27181606 ↗ May 2016 “the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate” PMID 26949137 ↗ Mar 2016 “Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis” NCT02782312 ↗ “Salbutamol(200µg), Salmeterol (50µg) and Fluticasone propionate (500µg) by inhalation” NCT03524066 ↗ “addition of a LABA (salmeterol) to an inhaled glucocorticoid (fluticasone propionate)” PMID 31553835 ↗ Sep 2019 “to receive fluticasone propionate plus salmeterol or fluticasone alone for 26 weeks.” PMID 27579634 ↗ Sep 2016 “Participants will inhale salmeterol 126 ug and fluticasone 270 ug twice daily” NCT06040268 ↗ “fluticasone/salmeterol 125/25 ug/puff, 2 puff bid plus salmeterol as-needed” NCT02556073 ↗ “inhaled fluticasone alone or in combination with salmeterol against placebo” PMID 18310480 ↗ Feb 2008 “Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder” NCT03562923 ↗ “Fluticasone Propionate / Salmeterol administered using CRC749 inhaler” NCT02474017 ↗ “both containing 500/50μg of the Fluticasone/Salmeterol combination.” NCT01484210 ↗ “combination product of salmeterol and fluticasone propionate (SFC)” NCT00456313 ↗ “Seretide(r) Evohaler(r): fixed combination fluticasone/salmeterol” NCT01070524 ↗ “salmeterol/fluticasone propionate (SAL/FP) 50/500 µg twice daily” PMID 25841237 ↗ Apr 2015 “fluticasone propionate/salmeterol (FP/SAL, branded) 500/50 mcg” PMID 27334739 ↗ Jun 2016 “50 µg salmeterol twice daily or 12 µg formoterol twice daily.” NCT00314574 ↗ “Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD” NCT00517634 ↗ “Fluticasone Propionate/Salmeterol DISKUS® 250/50mcg BID” NCT00857766 ↗ “Fluticasone Propionate/Salmeterol 250/50mcg Diskus BID” NCT01248975 ↗ “50/25 ug (fluticasone/salmeterol) 2 puffs twice daily” NCT01511367 ↗ “Fluticasone /salmeterol 250/50 combination capsule” NCT01521455 ↗ “Advair = fluticasone proprionate plus salmeterol” NCT00867737 ↗ “Fluticasone propionate/salmeterol combination” NCT00920959 ↗ “Salmeterol 50mcg Inhalation Powder” NCT01156792 ↗ “propionate/salmeterol HFA” NCT06572228 ↗ “Salmeterol 25 µg pMDI HFA” NCT01344655 ↗ “Salmeterol (inhaler)” NCT02790047 ↗ “Salmeterol” NCT02758873 ↗ “Salmeterol” NCT01802723 ↗ “salmeterol” NCT01907334 ↗ “Salmeterol” NCT03662711 ↗ NCT00471809 ↗ NCT00468975 ↗ NCT01706328 ↗ NCT01437995 ↗ NCT00685841 ↗ NCT00411372 ↗ NCT00497237 ↗ NCT00784550 ↗ NCT02270424 ↗ NCT00064402 ↗ NCT05776927 ↗ NCT02172287 ↗ NCT02972476 ↗ NCT00268216 ↗ NCT06654986 ↗ NCT01361984 ↗ NCT00448435 ↗ NCT03034915 ↗ NCT00197106 ↗ NCT01048333 ↗ NCT00530842 ↗ NCT00268177 ↗ NCT00549146 ↗ NCT02496715 ↗ NCT01147848 ↗ NCT03395002 ↗ NCT00706446 ↗ NCT00379028 ↗ NCT00655616 ↗ NCT02516592 ↗ NCT01124422 ↗ NCT02061280 ↗ NCT01117116 ↗ NCT03240575 ↗ NCT00662792 ↗ NCT01564199 ↗ NCT00662740 ↗ NCT02254226 ↗ NCT00350207 ↗ NCT00354874 ↗ NCT01181895 ↗ NCT00327353 ↗ NCT00422604 ↗ NCT00441441 ↗ NCT00127166 ↗ NCT00741767 ↗ NCT00525564 ↗ NCT02172794 ↗ NCT00605891 ↗ NCT00567996 ↗ NCT03461627 ↗ NCT00712335 ↗ NCT00908362 ↗ NCT00595361 ↗ NCT00116402 ↗ NCT00064415 ↗ NCT01391559 ↗ NCT01342913 ↗ NCT00200967 ↗ NCT03055988 ↗ NCT02024204 ↗ NCT00363480 ↗ NCT02477397 ↗ NCT00640484 ↗ NCT03394989 ↗ NCT00005110 ↗ NCT00395304 ↗ NCT06655012 ↗ NCT00379288 ↗ NCT04195867 ↗ NCT02446418 ↗ NCT01860066 ↗ NCT01225913 ↗ NCT01323634 ↗ NCT00479739 ↗ NCT01853787 ↗ NCT01555138 ↗ NCT00358358 ↗ NCT02238106 ↗ NCT04503460 ↗ NCT01243788 ↗ NCT00353873 ↗ NCT00559312 ↗ NCT00296491 ↗ NCT00346749 ↗ NCT02546349 ↗ NCT00242775 ↗ NCT00633217 ↗ NCT01709903 ↗ NCT01969721 ↗ NCT00245570 ↗ NCT00347139 ↗ NCT00452699 ↗ NCT00239499 ↗ NCT00556673 ↗ NCT01213693 ↗ NCT01209715 ↗ NCT04677959 ↗ NCT06657547 ↗ NCT00233051 ↗ NCT00914901 ↗ NCT02242227 ↗ NCT01794780 ↗ NCT00361959 ↗ NCT01795664 ↗ NCT00830505 ↗ NCT01817764 ↗ NCT03269318 ↗ NCT00452348 ↗ NCT01636076 ↗ NCT00291382 ↗ NCT03756883 ↗ NCT01892787 ↗ NCT00239421 ↗ NCT01772147 ↗ NCT00364273 ↗ NCT00449046 ↗ NCT00557440 ↗ NCT00403754 ↗ NCT00102882 ↗ NCT02980133 ↗ NCT01388595 ↗ NCT00144911 ↗ NCT02924688 ↗ NCT02254174 ↗ NCT00118690 ↗ NCT01772134 ↗ NCT03676413 ↗ NCT01536587 ↗ NCT00646594 ↗ NCT00531050 ↗ NCT01822899 ↗ NCT02232087 ↗ NCT00622635 ↗ NCT02136875 ↗ NCT03238482 ↗ NCT01762800 ↗ NCT00269126 ↗ NCT03207243 ↗ NCT01526161 ↗ NCT00736801 ↗ NCT01751113 ↗ NCT00214019 ↗ NCT00521222 ↗ NCT01231230 ↗ NCT00927758 ↗ NCT02218762 ↗ NCT01079130 ↗ NCT02256722 ↗ NCT03063086 ↗ NCT01908140 ↗ NCT01315249 ↗ NCT01255579 ↗ NCT02055352 ↗ NCT00615030 ↗ NCT00876694 ↗ NCT00156819 ↗ NCT00984659 ↗ NCT02254187 ↗ NCT02242253 ↗ NCT00503009 ↗ NCT01290874 ↗ NCT02558088 ↗ NCT00808288 ↗ NCT01393145 ↗ NCT01186653 ↗ NCT01131806 ↗ NCT00364442 ↗ NCT01834885 ↗ NCT02415179 ↗ NCT02758873 ↗ NCT00424008 ↗ NCT00563381 ↗ NCT06676319 ↗ NCT00355342 ↗ NCT00975195 ↗ NCT03387241 ↗ NCT00673478 ↗ NCT00115492 ↗ NCT00252863 ↗ NCT00950794 ↗ NCT00358488 ↗ NCT01657487 ↗ NCT01089127 ↗ NCT00821093 ↗ NCT02173691 ↗ NCT00158847 ↗ NCT01355991 ↗ NCT01312961 ↗ NCT00315744 ↗ NCT00351143 ↗ NCT02573233 ↗ NCT00527826 ↗ NCT00235053 ↗ NCT03363503 ↗ NCT01802723 ↗ NCT01696214 ↗ NCT00118716 ↗ NCT02388373 ↗ NCT01319019 ↗ NCT00274534 ↗ NCT00535366 ↗ NCT03158311 ↗ NCT01271556 ↗ NCT00274560 ↗ NCT01890863 ↗ NCT01172808 ↗ NCT02162485 ↗ NCT00529529 ↗ NCT00668772 ↗ NCT02301975 ↗ NCT02318043 ↗ NCT01172821 ↗ NCT00328718 ↗ NCT01323621 ↗ NCT00102765 ↗
Known as	408DP-02	“Salmeterol(408DP-02)：long-acting Beta2-agonist” NCT00950794 ↗
Known as	LIPO-202	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02483533 ↗ 5 NCT02397499 ↗ NCT02568319 ↗ NCT02397525 ↗ NCT03005717 ↗ NCT02398188 ↗
Known as	Racemic formoterol	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00685529 ↗
Known as	SAL	“The aim of this study was to compare the efficacy of FF/VI with fluticasone propionate (FP)/salmeterol (SAL) in patients with persistent asthma uncontrolled on a medium dose of ICS.” PMID 23846316 ↗ Oct 2013 6 “Subjects were randomized (1:1) to receive fluticasone propionate/salmeterol (FP/SAL) 100/50 mcg or FP 100 mcg prior to starting school.” PMID 26289742 ↗ Jun 2015 “salmeterol/fluticasone propionate (SFC) and salmeterol (SAL) that had primary endpoints of moderate/severe exacerbation rates” PMID 23613569 ↗ Apr 2013 “fluticasone propionate/salmeterol (FP/SAL) (inhaled corticosteroid/LABA)” PMID 26006754 ↗ May 2015 “salmeterol/fluticasone propionate (SAL/FP) 50/500 µg twice daily” PMID 25841237 ↗ Apr 2015 “An active control arm received salmeterol (SAL) twice daily.” PMID 24928338 ↗ Jun 2014 “fluticasone propionate/salmeterol 250/50 µg (FP/SAL)” PMID 28961020 ↗ Apr 2018
Known as	SAL 50	“Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease (COPD) in a Randomized, Double-Blind, Placebo-Controlled Study of Treatment with...” NCT00358358 ↗
Known as	SALM	“The purpose of this study is to optimise the device and/or formulation of the Fluticasone propionate (FP)/salmeterol (SALM) unit dose powder inhaler (Rotahaler) to achieve drug...” NCT01540708 ↗ 2 “The participants were then randomized to budesonide/formoterol (Bud + Form; 400/12 μg BID), fluticasone/salmeterol (Flu + Salm; 250/50 μg BID), or formoterol only (12 μg BID)...” PMID 34464242 ↗ Nov 2021 “high-dose salmeterol (SALM)/fluticasone (FP) maintenance plus an as-needed short-acting β(2)-agonist in Chinese patients with persistent uncontrolled asthma” PMID 22932169 ↗ Sep 2012
Known as	Salm25PE	“salmeterol (Salm25PE)” NCT00668772 ↗
Known as	Salm50DPI	“50 µg Salmeterol MDPI (Salm50DPI) twice daily (BID)” NCT00662792 ↗
Known as	salmeterol xinafoate	“Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of...” NCT01110200 ↗ 12 “Capsules containing salmeterol xinafoate 72.5 µg (equivalent to 50 µg of salmeterol) presented as powder for aspiration, packed in a plastic device in disk format, containing 60 doses” NCT01393145 ↗ “The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg).” NCT03034915 ↗ “Salmeterol xinafoate 50 mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.” NCT00355342 ↗ “Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®” NCT01636076 ↗ “fluticasone priopionate high dose and tiotropium inhalation and salmeterol xinafoate” NCT00975195 ↗ “Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 72.5 mcg” NCT02441114 ↗ “Salmeterol xinafoate and Fluticasone propionate HFA pMDI” NCT01795664 ↗ “Fluticasone propionate (FP)/ Salmeterol xinafoate (SLM)” NCT02113436 ↗ “Serevent (salmeterol xinafoate inhalation powder)” NCT01361984 ↗ “Drug: salmeterol xinafoate” NCT01802723 ↗ “Drug: Salmeterol xinafoate” NCT02242227 ↗ “Drug: Salmeterol Xinafoate” NCT04195867 ↗
Known as	Salmetrol Xinafoate	“Salmeterol Product Name: Serevent® Manufacturer: Allan and Hanbury's Active ingredients: Salmetrol Xinafoate Propellant: HFA 134a Dose: 25μg per actuation giving a total dose...” NCT01388595 ↗
Known as	Serevent	“Salmeterol Product Name: Serevent® Manufacturer: Allan and Hanbury's Active ingredients: Salmetrol Xinafoate Propellant: HFA 134a Dose: 25μg per actuation giving a total dose...” NCT01388595 ↗ 5 “Thus, the primary objective for the present study is to compare the two extremes of available long acting beta-agonist formulations - i.e. extra fine HFA formoterol ( Atimos )...” NCT01892787 ↗ “Pharmacokinetics of Salmeterol (Serevent®) After Inhalation With Metered Dose Inhaler (MDI) and Diskus® in Healthy Male Volunteers” NCT02254226 ↗ “Salmeterol 50 mcg (Serevent) via Diskus dry powder inhaler” NCT01361984 ↗ “Salmeterol 25 µg pMDI HFA (Serevent™)” NCT01344655 ↗ “salmeterol (Serevent, 50 µg b.i.d.)” NCT00239499 ↗
Known as	SEREVENT DISKUS	“A Randomised, Open-label Three-way Crossover Study to Evaluate the Pharmacokinetics of Salmeterol After Inhalation of a 25 μg and 50 μg Single Dose (Inhalation Powder, Hard PE...” NCT02254187 ↗ 3 “Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of...” NCT01110200 ↗ “a Free Combined Single Dose of 18 μg Tiotropium [Spiriva® HandiHaler®] and 50 μg Salmeterol [Serevent® Diskus®]” NCT02254174 ↗ “SEREVENT DISKUS® (Salmeterol) Inhlaer” NCT00346749 ↗
Known as	SLM	“Fluticasone propionate (FP)/ Salmeterol xinafoate (SLM)” NCT02113436 ↗
Known as	SN408D	“Salmeterol(SN408D)：long-acting Beta2-agonist” NCT00950794 ↗
Action	Activate	“a long-acting beta-agonist” NCT00156819 ↗
Modality	Other / unclassified	“a long-acting beta-agonist” NCT00156819 ↗
Route	Inhaled	“one group will get Salmeterol by multi-dose inhaler (MDI) 2 puffs 2 times a day” NCT00005110 ↗